PIV5 as oncolytic agent
The present invention includes the Paramyxovirus Parainfluenza Virus 5 (PIV5) as an oncolytic agent for treating various cancers, including, but not limited to breast cancer, lung cancer and melanoma. PIV5 oncolytic agents include both wild type PIV5 and various recombinant PIV5 constructs. Recombinant PIV5 constructs may include PIV5 lacking the conserved C-terminus of the V protein (PIV5VAC), PIV5 with mutations in the N-terminus of the V/P protein (PIV5CPI−), and PIV5 expressing MDA-7/IL-24 (rPIV5-MDA7), rPIV5-V/P-CPI−, rPIV5-CPI+, rPIV-Rev, rPIV5-RL, rPIV5-P-S157A, rPIV5-P-S308A, rPIV5-L-A1981D, rPIV5-F-S443P, rPIV5-MDA7, rPIV5ASH-CPI−, or rPIV5ASH-Rev. Also included are methods of making and using such oncolytic agents and compositions including such oncolytic agents.
1. A method of treating a subject with a cancer, the method comprising administering to the subject an effective amount of a composition comprising an isolated parainfluenza virus 5 (PIV5) virus, wherein the PIV5 virus consists of a virus of a wild type PIV5 strain or a commercial kennel cough vaccine PIV5 strain and wherein the PIV5 virus does not further comprise a nucleotide sequence encoding a heterologous polypeptide.
2. The method of claim 1 reducing the growth of a tumor cell, reducing tumor size, inducing tumor cells syncytia formation, and/or inducing apoptosis in a tumor cell.
3. The method of claim 1 , wherein the subject is a dog.
4. The method of claim 1 , wherein the tumor is a primary tumor and/or a metastatic tumor.
5. The method of claim 1 , wherein the tumor is selected from the group consisting of melanoma, basal cell carcinoma, colorectal cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer (including small-cell lung carcinoma and non-small-cell lung carcinoma), leukemia, lymphoma, sarcoma, ovarian cancer, Kaposi's sarcoma, Hodgkin's lymphoma, Non-Hodgkin's lymphoma, multiple myeloma, neuroblastoma, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, small-cell lung tumors, primary brain tumors, stomach cancer, head and neck cancers, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, cervical cancer, kidney cancer, endometrial cancer, glioblastoma, and adrenal cortical cancer.
6. The method of claim 1 , wherein administration of PIV5 is intratumoral, subcutaneous, intravenous, intranasal, intraperitoneal, intracranial, oral, or in situ.
7. The method of claim 1 further comprising administration of an additional therapeutic agent.
8. The method of claim 1 , wherein the cancer is a malignant solid tumor.
9. The method of claim 8 , wherein the malignant solid tumor comprises a sarcoma or a carcinoma.
10. The method of claim 1 , wherein administration of PIV5 is intratumoral.
11. The method of claim 1 , wherein the PIV5 virus consists of a virus of a wild type PIV5 strain selected from W3A, WR (ATCC Number VR-288), canine parainfluenza virus strain 78-238 (ATCC number VR-1573), or canine parainfluenza virus strain D008 (ATCC number VR-399).
12. The method of claim 1 , wherein the PIV5 virus consists of a virus of a known commercial kennel cough vaccine PIV5 strain.
13. The method of claim 1 , wherein the PIV5 virus consists of a virus of a commercial kennel cough vaccine PIV5 strain selected from BI commercial kennel cough vaccine strain, FD commercial kennel cough vaccine strain, Merck commercial kennel cough vaccine strain, or Merial commercial kennel cough vaccine strain.
14. A method of treating a subject with a cancer, the method comprising administering to the subject an effective amount of a composition comprising an isolated PIV5 mutant, wherein the PIV5 mutant consists of a mutation lacking the C-terminus of the V protein (rPIV5VΔC) and wherein the PIV5 mutant does not further comprise a nucleotide sequence encoding a heterologous polypeptide.
15. The method of claim 14 reducing the growth of a tumor cell, reducing tumor size, inducing tumor cells syncytia formation, and/or inducing apoptosis in a tumor cell.
16. The method of claim 14 , wherein the subject is a dog.
17. The method of claim 14 , wherein the tumor is a primary tumor and/or a metastatic tumor.
18. The method of claim 14 , wherein the tumor is selected from the group consisting of melanoma, basal cell carcinoma, colorectal cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer (including small-cell lung carcinoma and non-small-cell lung carcinoma), leukemia, lymphoma, sarcoma, ovarian cancer, Kaposi's sarcoma, Hodgkin's lymphoma, Non-Hodgkin's lymphoma, multiple myeloma, neuroblastoma, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, small-cell lung tumors, primary brain tumors, stomach cancer, head and neck cancers, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, cervical cancer, kidney cancer, endometrial cancer, glioblastoma, and adrenal cortical cancer.
19. The method of claim 18 , wherein the malignant solid tumor comprises a sarcoma or a carcinoma.
20. The method of claim 14 , wherein the cancer is a malignant solid tumor.
21. The method of claim 14 , wherein administration of PIV5 is intratumoral, subcutaneous, intravenous, intranasal, intraperitoneal, intracranial, oral, or in situ.
22. The method of claim 14 , wherein administration of PIV5 is intratumoral.
23. The method of claim 14 further comprising administration of an additional therapeutic agent.
24. A method of treating a dog with a malignant solid tumor, the method comprising the intratumoral administration into one or more malignant solid tumors of the dog an effective amount of a composition comprising an isolated parainfluenza virus 5 (PIV5), wherein the PIV5 virus consists of a virus of a wild type PIV5 strain or a commercial kennel cough vaccine PIV5 strain and wherein the PIV5 does not further comprise a nucleotide sequence encoding a heterologous polypeptide.